Novavax reaffirms FY2023 combined R&D and SG&A expense guidance of $1.15-1.25B

NOVAVAX INC

2023-FY EPS reported -$5.41 revenue$983,705,000

Reaffirmed full-year 2023 combined R&D and SG&A expenses anticipated between $1.15B and $1.25B.
Preliminary data as company finalizes 2023 financial results; Ernst & Young not audited.
Update provided at 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024.
Additional material information expected in final financial statements; caution against undue reliance.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

NOVAVAX INC updated its the year ended December 31, 2023 guidance (reaffirmed).

Period: the year ended December 31, 2023
Guidance: reaffirmed
Result: preliminary results

Exact text from the filing

On January 8, 2024, Novavax, Inc. (the “Company”) provided an update for investors in which it reaffirmed its guidance for full year 2023 combined research and development and selling, general and administrative expenses, which is anticipated to be between $1.15 billion and $1.25 billion.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

NOVAVAX INC filing history →

Source: SEC EDGAR

accession 0001104659-24-002100

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.